{
  "disease_name": "Tuberculosis",
  "icd10_codes": ["A15", "A16", "A17", "A18", "A19"],
  "red_flags": [
    {
      "symptom": "Hemoptysis (coughing blood)",
      "severity": "high",
      "action": "Immediate evaluation, chest X-ray, consider hospital admission",
      "timeframe": "within 1 hour"
    },
    {
      "symptom": "Severe respiratory distress",
      "severity": "critical",
      "action": "Oxygen therapy, urgent chest X-ray, rule out pneumothorax",
      "timeframe": "immediate"
    },
    {
      "symptom": "Signs of meningitis (neck stiffness, altered consciousness)",
      "severity": "critical",
      "action": "Lumbar puncture, start empiric TB meningitis treatment",
      "timeframe": "immediate"
    },
    {
      "symptom": "Severe weight loss (>10% body weight) or BMI < 16",
      "severity": "high",
      "action": "Nutritional assessment and support, start TB treatment",
      "timeframe": "within 24 hours"
    },
    {
      "symptom": "HIV co-infection with CD4 < 50",
      "severity": "critical",
      "action": "Immediate ART initiation within 2 weeks of TB treatment start",
      "timeframe": "within 24 hours"
    }
  ],
  "diagnostic_criteria": [
    {
      "category": "clinical",
      "criteria": [
        "Chronic cough > 2 weeks",
        "Night sweats",
        "Unintentional weight loss",
        "Fever > 2 weeks",
        "Contact with TB patient"
      ],
      "minimum_required": 2,
      "specificity": 0.3,
      "sensitivity": 0.7
    },
    {
      "category": "laboratory",
      "criteria": [
        "Positive sputum smear microscopy (AFB+)",
        "Positive GeneXpert MTB/RIF",
        "Positive sputum culture for M. tuberculosis",
        "Positive TB-LAM urine test (HIV+ patients)"
      ],
      "minimum_required": 1,
      "specificity": 0.98,
      "sensitivity": 0.85
    },
    {
      "category": "imaging",
      "criteria": [
        "Chest X-ray: upper lobe infiltrates",
        "Chest X-ray: cavitary lesions",
        "Chest X-ray: miliary pattern (TB dissemination)"
      ],
      "minimum_required": 1,
      "specificity": 0.6,
      "sensitivity": 0.75
    }
  ],
  "treatment_algorithm": [
    {
      "step_number": 1,
      "title": "Confirm Diagnosis",
      "description": "Obtain sputum samples and perform GeneXpert or smear microscopy",
      "medications": [],
      "duration": "Same day",
      "follow_up": "Results within 2 hours (GeneXpert) or 24 hours (smear)",
      "special_considerations": [
        "Collect 2 sputum samples: spot and early morning",
        "If unable to produce sputum, consider induced sputum or gastric aspirate (children)",
        "GeneXpert detects rifampicin resistance",
        "Start treatment empirically if strong clinical suspicion and cannot wait"
      ]
    },
    {
      "step_number": 2,
      "title": "Intensive Phase (2 months)",
      "description": "Daily directly observed therapy (DOT) with 4 drugs",
      "medications": [
        {
          "name": "RHZE Fixed-Dose Combination",
          "generic_name": "rifampicin-isoniazid-pyrazinamide-ethambutol",
          "dosage": "Weight-based: 150/75/400/275 mg FDC tablets",
          "route": "oral",
          "frequency": "Once daily",
          "duration": "2 months (8 weeks)",
          "contraindications": ["Severe liver disease", "Known drug allergy"],
          "side_effects": ["Orange urine/tears", "Hepatotoxicity", "Peripheral neuropathy", "Visual changes"],
          "cost_usd": 20.0
        },
        {
          "name": "Pyridoxine (Vitamin B6)",
          "generic_name": "pyridoxine",
          "dosage": "25-50 mg daily",
          "route": "oral",
          "frequency": "Once daily",
          "duration": "Throughout TB treatment",
          "contraindications": [],
          "side_effects": [],
          "cost_usd": 2.0
        }
      ],
      "duration": "2 months",
      "follow_up": "Monthly sputum, liver function tests at baseline and 1 month",
      "special_considerations": [
        "DOT mandatory - observe patient swallowing medications",
        "Take medications on empty stomach (1 hour before food)",
        "Monitor for hepatotoxicity (jaundice, nausea, abdominal pain)",
        "Check visual acuity monthly (ethambutol toxicity)"
      ]
    },
    {
      "step_number": 3,
      "title": "Continuation Phase (4 months)",
      "description": "Daily therapy with 2 drugs after negative sputum at 2 months",
      "medications": [
        {
          "name": "RH Fixed-Dose Combination",
          "generic_name": "rifampicin-isoniazid",
          "dosage": "Weight-based: 150/75 mg or 300/150 mg FDC",
          "route": "oral",
          "frequency": "Once daily",
          "duration": "4 months (16 weeks)",
          "contraindications": ["Severe liver disease"],
          "side_effects": ["Orange urine", "Hepatotoxicity", "Peripheral neuropathy"],
          "cost_usd": 15.0
        }
      ],
      "duration": "4 months",
      "follow_up": "Monthly clinic visits, sputum at end of treatment",
      "special_considerations": [
        "Total treatment duration: 6 months for new pulmonary TB",
        "Extend to 8-12 months for TB meningitis, bone/joint TB",
        "Continue pyridoxine throughout",
        "Patient can stop DOT if adherent and tolerating well"
      ]
    },
    {
      "step_number": 4,
      "title": "MDR-TB Treatment (if rifampicin resistant)",
      "description": "Longer treatment with second-line drugs - REFER TO SPECIALIST",
      "medications": [
        {
          "name": "Bedaquiline-based regimen",
          "generic_name": "bedaquiline + linezolid + others",
          "dosage": "Individualized based on resistance pattern",
          "route": "oral",
          "frequency": "Daily",
          "duration": "9-20 months",
          "contraindications": ["QT prolongation"],
          "side_effects": ["QT prolongation", "Neuropathy", "Bone marrow suppression"],
          "cost_usd": 1500.0
        }
      ],
      "duration": "9-20 months",
      "follow_up": "Monthly sputum culture, ECG monitoring",
      "special_considerations": [
        "Requires expert consultation",
        "Social support critical for long treatment",
        "Monitor for drug interactions with ARVs"
      ]
    }
  ],
  "differential_diagnosis": [
    {
      "condition": "Bacterial pneumonia",
      "icd10_code": "J18.9",
      "distinguishing_features": [
        "Acute onset (days not weeks)",
        "High fever with rigors",
        "Responds to antibiotics in 48-72 hours",
        "Lobar consolidation on X-ray"
      ],
      "prevalence": "common"
    },
    {
      "condition": "Lung cancer",
      "icd10_code": "C34.9",
      "distinguishing_features": [
        "Age > 50, smoking history",
        "Mass lesion on chest X-ray",
        "Weight loss without fever",
        "Negative TB tests"
      ],
      "prevalence": "uncommon"
    },
    {
      "condition": "HIV-related pneumonia (PCP)",
      "icd10_code": "B59",
      "distinguishing_features": [
        "HIV+ with CD4 < 200",
        "Dry cough, progressive dyspnea",
        "Bilateral interstitial infiltrates",
        "Elevated LDH"
      ],
      "prevalence": "common"
    },
    {
      "condition": "Bronchiectasis",
      "icd10_code": "J47.9",
      "distinguishing_features": [
        "Chronic productive cough with purulent sputum",
        "Recurrent infections",
        "Dilated bronchi on CT scan"
      ],
      "prevalence": "uncommon"
    }
  ],
  "complications": [
    {
      "name": "Drug-induced hepatitis",
      "risk_factors": ["Pre-existing liver disease", "Alcohol use", "HIV co-infection"],
      "prevention": "Baseline and monthly liver function tests",
      "management": "Stop all TB drugs if ALT > 5x normal or jaundice; reintroduce sequentially"
    },
    {
      "name": "Peripheral neuropathy",
      "risk_factors": ["Isoniazid use", "HIV", "Diabetes", "Malnutrition"],
      "prevention": "Pyridoxine 25-50 mg daily",
      "management": "Increase pyridoxine to 100-200 mg daily"
    },
    {
      "name": "TB-IRIS (Immune Reconstitution Inflammatory Syndrome)",
      "risk_factors": ["HIV co-infection", "Low CD4", "Starting ART soon after TB treatment"],
      "prevention": "Delay ART 2-8 weeks after TB treatment start",
      "management": "Continue TB/ART, add prednisone 1 mg/kg for severe cases"
    },
    {
      "name": "Hemoptysis",
      "risk_factors": ["Cavitary disease", "Bronchiectasis"],
      "prevention": "Adequate TB treatment to heal cavities",
      "management": "Bed rest, antifibrinolytics, bronchoscopy/surgery if massive"
    }
  ],
  "prevention": [
    {
      "type": "primary",
      "intervention": "BCG vaccination at birth",
      "target_population": "All infants in TB-endemic countries",
      "effectiveness": "Prevents severe TB (meningitis, miliary) in children by 70-80%, limited effect on pulmonary TB"
    },
    {
      "type": "primary",
      "intervention": "TB preventive therapy (TPT) for contacts",
      "target_population": "Household contacts of TB patients, especially children < 5 and HIV+",
      "effectiveness": "Isoniazid 6 months reduces TB risk by 60%, 3HP (isoniazid + rifapentine 3 months) by 90%"
    },
    {
      "type": "secondary",
      "intervention": "Contact tracing and screening",
      "target_population": "All household and close contacts of TB patients",
      "effectiveness": "Identifies 5-10% of contacts with active TB"
    },
    {
      "type": "tertiary",
      "intervention": "Airborne infection control in healthcare",
      "target_population": "Healthcare facilities",
      "effectiveness": "Natural ventilation, UV lights, N95 masks reduce nosocomial transmission"
    }
  ],
  "references": [
    {
      "title": "WHO Guidelines on TB treatment",
      "source": "WHO",
      "url": "https://www.who.int/publications/i/item/9789240063129",
      "year": 2022,
      "evidence_level": "A"
    },
    {
      "title": "WHO TB/HIV guidance",
      "source": "WHO",
      "url": "https://www.who.int/publications/i/item/978-92-4-155023-9",
      "year": 2023,
      "evidence_level": "A"
    },
    {
      "title": "CDC TB Treatment Guidelines",
      "source": "CDC",
      "url": "https://www.cdc.gov/tb/publications/guidelines/treatment.htm",
      "year": 2023,
      "evidence_level": "A"
    }
  ]
}
